BioNTech to Acquire Biotheus for $800 Million to Expand Oncology Portfolio
BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million, securing full global rights to BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.
BioNTech to buy bispecific antibody developer Biotheus for up to $950M
BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M in cash and American depositary shares to acquire all ...
BioNTech Acquires Biotheus to Enhance Cancer Therapies
BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its
BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech SE (Nasdaq: BNTX, "BioNTech") and Biotheus ("Biotheus") today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.
BioNTech To Buy Biotheus In Upfront Payment Of $800 Mln
BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company
BioNTech to Acquire Biotheus in $950 Million Deal
The tie-up will also expand BioNTech's footprint in China, giving it a local research and development hub for clinical trials, as well as a new biologics manufacturing facility and more than 300 Biotheus employees,
Business Insider1h
BioNTech to acquire Biotheus for upfront consideration of $800M
BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of ...
Yahoo Finance2h
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
What Analysts Are Saying About BioNTech Stock
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...
Fintel on MSN4d
Goldman Sachs Upgrades BioNTech SE - Depositary Receipt () (BNTX)
Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...
BioNTech (BNTX) Scheduled to Post Quarterly Earnings on Monday
BioNTech (NASDAQ:BNTX – Get Free Report) will be announcing its earnings results before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($1.06) per share ...
Nasdaq9d
BNTX Earnings: BioNTech Reports Better-than-Expected Q3 Earnings, Lowers Revenue Outlook
Shares of BioNTech (BNTX) gained in pre-market trading after the company reported better-than-expected Q3 earnings. The biotech company’s earnings increased by 22.7% to €0.81 ($0.89 ...
Deutsche Bank Reaffirms Their Buy Rating on BioNTech SE (BNTX)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...